Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research from S.D. Reed and co-authors in the area of breast cancer published
July 9th, 2009
According to recent research from the United States, " Using data from a recent randomized trial, we evaluated the cost effectiveness of ixabepilone plus capecitabine versus capecitabine alone in patients with predominantly metastatic breast cancer considered to be taxane-resistant and previously treated with or resistant to an anthracycline. We developed a stochastic decision-analytic model to represent data collected in the trial on medical resource use, health-related quality of life, and clinical outcomes." "Estimates of overall survival were conditional on level of tumor response. We assigned monthly costs and utility weights according to periods defined by the...
Source: Women's Health Weekly (2009-07-09)
|
